Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
What is the optimal platelet count threshold for prophylactic platelet transfusions to minimize bleeding, platelet use, and adverse clinical outcomes in thrombocytopenic patients with hematological malignant neoplasms?
Maintaining a higher platelet count threshold (≤20 × 109/L or ≤30 × 109/L) was not associated with less bleeding than the current standard (≤10 × 109/L), but required more platelet transfusions (low-quality evidence).
Estcourt LJ, Stanworth SJ, Murphy MF. Different Platelet Count Thresholds to Guide Use of Prophylactic Platelet Transfusions for Patients With Hematological Disorders After Myelosuppressive Chemotherapy or Stem Cell Transplantation. JAMA Oncol. 2016;2(8):1091–1092. doi:10.1001/jamaoncol.2016.2466
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: